Delivery Order SPE2DB22D3501-SPE2DB25FVZ44

Award Date 6/10/25
Potential Completion Date 6/11/25
Potential Value $1.7K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Vyvanse 50 mg capsules. The $6,677.04 contract has a period of performance through July 2024 and is a firm fixed-price delivery order. The contract is not a set-aside award. AmerisourceBergen holds an Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical valued up to $999,999,999 through December 2025 for providing a...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of Vyvanse 40 mg capsules. The contract has a ceiling value of $4,700.14 and a period of performance through April 30, 2025. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00, which serves as a comprehensive global pharmaceutical support vehicle through December 2026....
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Vyvanse 20mg capsules. The $2,675.40 fixed-price contract has a completion date of December 12, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical to provide a comprehensive range of pharmaceutical products and medical supplies, including specialty medications, generic drugs,...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Vyvanse 40 mg capsules. The $1,860.27 firm fixed price contract has a completion date of January 17, 2025. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the primary vehicle for providing a comprehensive range of pharmaceutical products and medical...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor, for the supply of Vyvanse 40 mg capsules. The contract has a ceiling value of $9,227.86 and a performance period ending on August 8, 2024. It is a firm-fixed-price contract, with no set-aside designation. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued up to $999,999,999 through December...
This is a delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp for the supply of Vyvanse 40 mg capsules. The contract has a firm fixed price of $2,586.00 and a completion date of July 19, 2024. AmerisourceBergen is a major pharmaceutical distributor that holds several Indefinite Delivery Contracts (IDCs) with federal agencies, including a $999,999,999 IDC with DLA Troop Support Medical for a wide range of medical commodities. This...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of Vyvanse 60 mg capsules. The order, valued at $1,047.82, is a firm-fixed price contract with a completion date of September 23, 2024. Amerisourcebergen holds an Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, to provide a comprehensive range of medical commodities,...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Vyvanse 20 mg capsules. The contract has a ceiling value of $2,668.88 and a period of performance through April 11, 2025. The contract is a firm-fixed-price delivery order, with no set-aside designation, indicating open competition. AmerisourceBergen Drug Corp holds a substantial Indefinite Delivery Contract (IDC) with the DLA Troop...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, for the supply of Vyvanse 20 mg capsules. The contract has a ceiling value of $2,211.08 and a completion date of May 19, 2025. It is a firm-fixed-price delivery order contract, with no set-aside designation. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Vyvanse 40mg capsules. The contract has a total ceiling value of $3,970.91 and runs through October 2024. It is a firm-fixed-price contract, with no set-aside designation. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and expiring in November 2026. This...
  • SPE2DB22D3501
    Indefinite Delivery Contract
  • SPE2DB22D3501-SPE2DB25FVZ44
    Delivery Order

This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, for the supply of Vyvanse 40mg capsules. The $1,700.65 firm-fixed-price contract has a period of performance through June 2025 and is not designated as a set-aside award. AmerisourceBergen Drug Corp holds a substantial Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999.00, which serves as a comprehensive global pharmaceutical support vehicle for the military healthcare system through December 2026.

Generated 9/9/25, 12:53 PM